Hikma Pharmaceuticals invests $1B to expand pharmaceutical manufacturing and R&D facilities in Ohio and New Jersey
Hikma Pharmaceuticals USA has announced plans to expand its pharmaceutical manufacturing and research and development capabilities in Columbus and Cleveland, Ohio, and Cherry Hill and Dayton, New Jersey. The company, which develops and manufactures a wide range of essential generic and injectable medicines, is investing $1 billion into the project and currently employs 2,300 people across its U.S. operations.
This expansion—part of the company’s long-term strategy to increase U.S.-based medicine production—will enhance capacity across four facilities. The upgrades will strengthen Hikma’s portfolio of more than 800 medicines and expand its ability to manufacture high volumes of injectable and oral solid products for American hospitals and healthcare providers.
What people are saying
In a recent quote, Dr. Hafrun Fridriksdottir, President, Hikma Rx, said, “We are proud to continue our ongoing investments in US manufacturing and R&D to better serve the needs of American patients. Hikma and our 2,300 dedicated US people are committed to supporting healthier communities nationwide by providing Americans with a steady and reliable supply of domestically produced quality medicines.”
Dr. Bill Larkins, President, Hikma Injectables, added, “Over the past 15 years Hikma has grown to become a top three US supplier of sterile injectable medicines with more than 180 injectable products in our portfolio and a growing pipeline. This new phase of US investment will enhance and expand our sterile injectables production capabilities and enable us to continue providing our broad portfolio of essential medicines to US patients.”
Manufacturers investing in Ohio
Mars invests $450M to open pet food manufacturing facility in Ohio
The new Royal Canin facility will produce enough dry pet food to feed 4 million cats and dogs annually.
United Alloy invests $48M to expand data center component manufacturing facility in Ohio
The expansion adds 350,000 square feet of space and will bring more than 400 total jobs to the Union area.
Amgen invests $900M to expand biologic medicines manufacturing facility in Ohio
This expansion brings Amgen’s total investment in Central Ohio to over $1.4 billion.
Investing in American manufacturing in 2025
This map shows where manufacturers are choosing to invest their resources, whether they are building new production facilities or expanding existing plants.
About the Author
Alexis GajewskiAlexis Gajewski
Senior Content Strategist
Alexis Gajewski is a manufacturing writer and editor with nearly 20 years of experience covering the people, practices, and technologies that keep industrial facilities running. For more than a decade, she served as Senior Content Strategist for Plant Services, creating content for plant managers, engineers, and maintenance professionals on a variety of industrial topics.
During her tenure, Alexis worked to develop the brand’s digital strategy and helped launch and produce Great Question: A Manufacturing Podcast. She also created The Lighter Side of Manufacturing, a weekly blog that explored the inventive and sometimes humorous side of the industry.
Alexis co-founded Influential Women in Manufacturing, a recognition program that honored 49 women in its first two years, earned an industry award for Best Product Launch, and received a proclamation from Illinois Governor JB Pritzker and a commendation from U.S. Senator Tammy Duckworth.
She also led newsroom operations and development at a large media company where she set editorial standards, developed training curriculum, and helped support AI adoption for more than 150 editors across 80+ brands spanning manufacturing, industrial processing, automation, and more.
Additionally, Alexis works as a freelance writer and editor, and her areas of interest include continuous improvement, the skilled workforce, and the role of emerging technology on the plant floor.
Connect with Alexis on LinkedIn
